Genome Engineering for Humanity
PIPELINE
HM-001
Monoclonal antibody
HM-001
Solid tumors
- Oncology
- Discovery stage
- Immune checkpoint inhibitor
-
Indications
Solid tumors
-
Mechanism of Action
HM-001 is a fully human monoclonal antibody that is developed from our SynThese™ platform. A direct targeting immune checkpoint molecule effectively restores T-cell effector functions in the immunosuppressive tumor microenvironment.
-
Development status
This early discovery asset is currently set for preclinical studies. HuMab initiated a business development strategy with a top priority, thoroughly investigating medical unmet needs in immunotherapy regimens for solid tumors and envisioning novel therapy modalities in combination with our proprietary CPP technology.